Revvity, Inc
Revvity is a U.S.-based health science company that develops instruments, software, reagents, and services used across research, screening, diagnostics, and reproductive health workflows. Its business spans translational multi-omics, biomarker discovery, imaging, informatics, and diagnostic testing, with products and services sold globally from its headquarters in Waltham, Massachusetts.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInstruments, reagents, and consumables used in research and discovery workflows.
Informatics and workflow software used to manage scientific and lab data.
Diagnostic assays and systems used in clinical and laboratory testing.
Screening and diagnostic products used in prenatal and reproductive testing.
Products
Reported · share of revenue- Products83.7 %
- Services16.3 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Revvity sells to research institutions, biopharma and biotech companies, clinical laboratories, and healthcare providers that need specialized tools for discovery, screening, and diagnosis. It also serves public and private organizations involved in reproductive health and disease testing, where workflow reliability, regulatory compliance, and analytical performance matter. The company markets through specialized sales forces and distributors, so customer relationships are typically technical and application-driven rather than transactional.
Buy instruments, reagents, and software for discovery, biomarker, and translational research.
Buy workflow technologies for screening, assay development, and development-stage research.
Buy immunodiagnostics systems and assays for routine and specialized testing.
Buy prenatal screening and reproductive diagnostic products used in clinical workflows.
Buy integrated testing and informatics solutions to support lab operations and reporting.
Strategy
Revvity’s strategy centers on expanding in high-growth health science markets by broadening its product and service offerings and investing in research and development. It also emphasizes innovation, acquisitions of technology, and global commercial reach to strengthen its position across discovery, screening, and diagnostics workflows.
A wider portfolio increases cross-sell opportunities and makes the company more embedded in customer workflows.
The market changes quickly, so timely product launches are needed to defend share and support growth.
A broad international footprint supports access to more customers and reduces dependence on any one market.
Geography
Q2/2026Revvity markets its products and services in more than 160 countries and operates sales and service teams in about 40 countries. The company is headquartered in the United States, but its business is internationally diversified, with sales outside the U.S. representing the majority of revenue and with manufacturing, employees, and suppliers also located abroad.
Share of the revenue the company reports by geography.
Risks
Revvity faces demand, regulatory, and technology risks because its products are sold into healthcare and research markets that depend on funding, approvals, and rapid innovation. Its international footprint also exposes it to foreign exchange, trade, and geopolitical effects, while goodwill and acquisition-related assets require ongoing impairment testing.
- Market demand tied to funding and economic conditionsImpact: HighLikelihood: High
Customers in research and healthcare may delay purchases when budgets or approvals are uncertain.
Exposure: Research tools and diagnostics demand
- Regulatory compliance riskImpact: HighLikelihood: Medium
Some products are subject to FDA and foreign agency oversight, and non-compliance can restrict sales.
Exposure: Diagnostics and regulated healthcare products
- Technology obsolescence and product launch timingImpact: HighLikelihood: Medium
The industry changes quickly, so delayed or weak new products can lead to share loss.
Exposure - Foreign exchange and international operating riskImpact: MediumLikelihood: Medium
Most revenue is generated outside the U.S., and many suppliers and employees are abroad.
Exposure: Global sales and manufacturing footprint
- Goodwill impairment riskImpact: MediumLikelihood: Medium
Acquisition-related goodwill depends on future cash flow assumptions and market valuations.
Exposure: Reporting units and acquired businesses
Accounting
Judgemental itemsThe company has multiple reporting units and uses discounted cash flow assumptions that can materially change carrying values.
Impact: Could create non-cash impairment charges if expected cash flows weaken
Business combinations create identifiable intangible assets that affect amortization and future earnings.
Impact: Affects operating income and balance sheet valuation
A majority of sales are outside the U.S., so exchange rates affect reported revenue and profitability.
Impact: Can move reported growth and margins without changing underlying demand
Collections timing, including in China, can shift operating cash flow between periods.
Impact: Affects quarterly and annual cash conversion
Similar listed companies
Publicly listed companies with a comparable business focus.
Repligen Corporation
RGEN · Biological Products, (No Diagnostic Substances)
Celularity Inc
CELU · Pharmaceutical Preparations
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
Veracyte, Inc
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
Seres Therapeutics, Inc.
MCRB · Pharmaceutical Preparations
BioLife Solutions, Inc
BLFS · Electromedical & Electrotherapeutic Apparatus
Last updated: 24/09/2026